Could a simple protein infusion limit stroke damage?
NCT ID NCT07415655
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether a low dose of albumin, a natural blood protein, can protect brain tissue after an ischemic stroke. One hundred participants will receive either albumin or a placebo during a standard procedure to restore blood flow. The goal is to see if albumin reduces brain injury and improves neurological outcomes over 90 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Albumin (human serum albumin)
What this could lead to
If it works, this could point toward a simple, safe treatment to limit brain damage after a stroke and improve patients' recovery.
What could go wrong
This is an early Phase 2 trial with only 100 people, so results may not be conclusive. The benefit over standard care is unproven, and albumin may not protect the brain as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Hradec Kralove
RECRUITINGHradec Králové, Czech Republic, 50005, Czechia
Contact Phone: •••-•••-•••• Email: •••••@•••••